Research Associate/Sr. Research Associate, Histology

About Voyager

We are Voyager Therapeutics, a pre-clinical stage biotech compelled by curiosity and powered by persistence. Voyagers are bold innovators who are energized in unlocking the full potential of AAV gene therapy employing our TRACERTM capsid discovery platform. Our resolve is to advance the field of AAV gene therapy, and through our innovative capsids, we are extending the reach and impact of our technology to help more patients in need.

Recognizing that we can expand on the experience, innovation, and outcomes that propel our efforts by working together, we actively seek diverse views. If you’re someone who wants to make discoveries that change the landscape of medicine for patients, we want you on our team!

Job Summary

Reporting to the Senior Scientist, the Research Associate OR Senior Research Associate will contribute to Voyager’s research team at its facility in Cambridge, Massachusetts. This is a hands-on position for a person committed to helping the broader team conduct innovative drug discovery research in a collaborative environment. We are seeking a person who is enthusiastic about biomedical research and can work in close partnership with other scientists and team members. This is an ideal position for an individual with extensive experience in immunohistochemistry (IHC), immunofluorescence (IF), and in-situ hybridization (ISH) assay development. The ideal candidate will demonstrate thorough knowledge of experimental design and independent thinking to support multiple programs. The RA or S. RA must be a highly motivated individual with the ability to oversee project timelines and deliverables and interpret and communicate results.

Key Responsibilities

• Develop and perform novel tissue-based staining methodologies immunohistochemistry (IHC), immunofluorescence (IF), and in-situ hybridization (ISH) assay development
• Subsequent image acquisition of the stained tissues whole slide scanners such as Olympus VS 200 or Aperio Versa, epifluorescence and confocal microscopy
• Perform image analysis using Halo software utilizing various analysis modules and Artificial Intelligence Classifiers followed by data analysis using Excel, GraphPad Prism or Spotfire
• Handle and process fresh frozen and fixed nervous-and peripheral- tissues from rodents, non-human primates, and human
• Contribute to experimental design, planning, and execution of research projects
• Collaborate with project team members and peers to anticipate and resolve day-to-day issues working in a matrix organizational structure
• Oversee histology infrastructure and enable and improve processes, workflow, and databases to support research activities

Qualifications

• For RA, BS with 2+ years or MS with 1+ years relevant industry experience
• For Senior RA, BS with 3+ years or MS with 2+ years relevant industry experience
• Extensive experience with using IHC/ISH automated staining systems preferably Ventana Discovery Ultra and Leica BondRx
• Exhibit excellent oral and written communication skills

Preferred

• Knowledge and working experience with the anatomy of brain and spinal cord of rodents, non-human primates, and human
• Experience in image acquisition using; whole slide scanners such as Olympus VS 200 or Aperio Versa, epifluorescence and confocal microscopy
• Experience in image analysis using Halo or Visiopharm or Defeniens or Image J
• Familiarity with newer histology-based precision profiling techniques and data analysis, such as in-situ sequencing or MERFISH or Visium spatial transcriptomics or Nanostring’s Digital Spatial Profiling or Spatial Molecular Imager

Voyager Therapeutics requires all U.S. new hires to be fully vaccinated for COVID-19 prior to the first date of employment.  Voyager Therapeutics will consider reasonable accommodations as required by federal, state, and local laws.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis and Neurocrine Biosciences as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes preclinical programs in Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS), each with validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.